... no activation of prothrombin or thrombin, as indicated by appearance of thrombogenicity markers such as fibrinopeptide A and the amino-terminal fragments of prothrombin (F 1+2 ). Other authors demonstrated that in patients at high risk for thrombotic complications, particularly those with liver disease...

...Steven A. Limentani; Kerry P. Gowell; Steven R. Deitcher Constituents other than factor IX have been implicated as etiologic agents for thrombotic complications in patients receiving prothrombin complex concentrates (PCCs). In vitro studies, in vivo animal models, and clinical evaluations...